A pilot study of urinary estrogen metabolites (16α-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 3, 1997, Pages 601-605

  Ursin, Giske ^a   London, Stephanie ^a,b   Stanczyk, Frank Z ^a   Gentzschein, Elisabet ^a   Paganini Hill, Annlia ^a   Ross, Ronald K ^a   Pike, Malcolm C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

16 hydroxyestrone; 2 hydroxyestrone; Breast cancer; Estrogen metabolism; Urinary estrogen metabolites

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE;

ADULT; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; FEMALE; HUMAN; HYDROXYLATION; METABOLITE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; URINALYSIS;

EID: 0030911797     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s3601     Document Type: Conference Paper

References (49)

1. Henderson BE, Ross RK, Bernstein L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48:246-253 (1988).
2. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 48:605-613 (1972).
3. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:307-314 (1973).
4. Lubin F, Ruder AM, Wax Y, Modan B. Overweight and changes in weight throughout adult life in breast cancer etiology. Am J Epidemiol 122:579-588 (1985).
5. England PC, Skinner LG, Cottrell KM, Sellwood RA. Serum estradiol-17β in women with benign and malignant breast disease. Br J Cancer 30:571-576 (1974).
6. McFadyen IJ, Prescott RJ, Groom GV, Forrest APM, Golder MP, Fahmy DR. Circulating hormone concentrations in women with breast cancer. Lancet ii:1100-1102 (1976).
7. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res 37:4655-4659 (1977).
8. Adami HO, Johansson EDB, Vegelius J, Victor A. Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls. Upsala J Med Sci 84:259-274 (1979).
9. Drafta D, Schindler AF, Milicu M, Keller E, Stroe E, Horodniceanu E, Balanescu I. Plasma hormones in pre- and postmenopausal breast cancer. J Steroid Biochem 43:793-802 (1980).
10. Moore JW, Clark GMG, Bulbrook RD, Hayward JL, Murai JT, Hammond GL, Siiteri PK. Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int J Cancer 29:17-21 (1982).
11. Reed MJ, Cheng RW, Noel CT, Dudley HAF, James VHT. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 43:3940-3943 (1983).
12. Reed MJ, Beranek PA, Cheng RW, Ghilchik MW, James VHT. The distribution of oestradiol in plasma from postmenopausal women with or without breast cancer: relationships with metabolic clearance rates of oestradiol. Int J Cancer 35:457-460 (1985).
13. Secreto G, Recchione C, Cavalleri A, Miraglia M, Dati V. Circulating levels of testosterone, 17β-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer 47:269-275 (1983).
14. Bruning PF, Bonfrer JMG, Hart AAM. Non-protein bound oestradiol, sex hormone binding globulin and breast cancer risk. Br J Cancer 51:479-484 (1985).
15. Siiteri PK, Simberg N, Murai J. Estrogens and breast cancer. Ann NY Acad Sci 464:100-105 (1986).
16. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 25:791-799 (1987).
17. Persson BH, Risholm L. Oophorectomy and cortisone treatment as a method of eliminating estrogen production in patients with breast cancer. Acta Endocrinol 47:15-26 (1964).
18. Marmorston J, Crowley LG, Myers SM, Stern E, Hopkins CE. II: Urinary excretion of estrone, estradiol, and estriol by patients with breast cancer and benign breast disease. Am J Obstet Gynecol 4:460-467 (1965).
19. Arguelles AE, Hoffman C, Poggi UL, Chekherdemian M, Saborida C, Blanchard O. Endocrine profiles and breast cancer. Lancet i:165-167 (1973).
20. Gronroos M, Aho AJ. Estrogen metabolism in postmenopausal women with primary and recurrent breast cancer. Eur J Cancer 4:523-527 (1968).
21. Grattarola R, Secreto G, Recchione C, Castellini W. Androgens in breast cancer. Am J Obstet Gynecol 118:173-178 (1974).
22. Thijssen JHH, Poortman J, Schwarz F. Androgens in postmenopausal breast cancer: excretion, production and interaction with estrogens. J Steroid Biochem 6:729-734 (1975).
23. Morreal CE, Dao TL, Nemoto T, Lonergan PA. Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. J Natl Cancer Inst 63:1171-1174 (1979).
24. Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE. Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. Br J Cancer 61:298-302 (1990).
25. Adlercreutz H, Fotsis T, Höckerstedt K, Hämäläinen E, Bannwart C, Bloigu S, Valtonen A, Ollus A. Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem 34:527-530 (1989).
26. Clark JH, Paszko Z, Peck EJ Jr. Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol. Endocrinol 100:91-96 (1977).
27. Fishman J, Martucci C. Biological properties of 16α-hydroxyoestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrin Metab 51:611-615 (1980).
28. Martucci C, Fishman J. Direction of estradiol metabolism as a control of its hormonal action - uterotrophic activity of estradiol metabolites. Endocrinol 101:1709-1715 (1977).
29. Bradlow HL, Hershcopf RJ, Fishman JF. Oestradiol 16α-hydroxylase: a risk marker for breast cancer. Cancer Surv 5:574-583 (1986).
30. Bradlow HL, Hershcopf R, Martucci C, Fishman J. 16α-Hydroxylation of estradiol: a possible risk marker for breast cancer. Ann NY Acad Sci 464:138-151 (1986).
31. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA 82:6295-6299 (1985).
32. Osborne MP, Bradlow HL, Wong GYC, Telang NT. Upregulation of estradiol C16α-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 85:1917-1920 (1993).
33. Schneider J, Kinne D, Fracchia A, Pierce V, Bradlow HL, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79:3047-3051 (1982).
34. Osborne MP, Karmali RA, Hershcopf RJ, Bradlow HL, Kourides IA, Williams WR, Rosen PP, Fishman J. Omega-3 fatty acids: modulation of estrogen metabolism and potential for breast cancer prevention. Cancer Invest 8:629-631 (1988).
35. Longnecker MP, Paganini-Hill A, Ross RK. Lifetime alcohol consumption and breast cancer risk among postmenopausal women in Los Angeles. Cancer Epidemiol Biomarkers Prev 4:721-725 (1995).
36. Bland KI, Copeland EM III. The Breast: Comprehensive Management of Benign and Malignant Diseases. Philadelphia:W.B. Saunders, 1991.
37. Fishman J, Hellman L, Zumoff B, Gallagher TF. Influence of thyroid hormone on estrogen metabolism in man. J Clin Endocrinology 22:389-392 (1962).
38. Galbraith RA, Michnovicz JJ. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 321:269-274 (1989).
39. 3H mouse. Steroids 55:114-119 (1990).
40. Niwa T, Bradlow HL, Fishman J, Swaneck GE. Induction and inhibition of estradiol hydroxylase activities in MCF-7 human breast cancer cells in culture. Steroids 55:297-302 (1990).
41. Klug TL, Bradlow HL, Sepkovic DW. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16α-hydroxyestrone in urine. Steroids 59:648-655 (1994).
42. Katagiri H, Stanczyk FZ, Goebelsmann U. Estriol in pregnancy. III: Development, comparison and use of specific antisera for rapid radioimmunoassay of unconjugated estriol in pregnancy plasma. Steroids 24:225-238 (1974).
43. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 159:1540-1546 (1988).
44. Cassidenti DL, Vijod AG, Vijod MA, Stanczyk FZ, Lobo RA. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol 163:1953-1960 (1990).
45. Ziegler RG, Rossi SC, Fears TR, Bradlow HL, Aldercreutz H, Sepkovic D, Kiuru P, Wahala K, Vaught JB, Falk RT, Donaldson JL, Gail MH, Siiteri PK, Hoover RN. Quantifying estrogen metabolism: establishing the reproducibility and validity of assays for 2-hydroxyestrone and 16α-hydroxyestrone in urine. Environ Health Perspect 105(Suppl 3):607-614 (1997).
46. Musey PI, Collins DC, Bradlow HL, Gould KG, Preedy JRK. Effect of diet on oxidation of 17β-estradiol in vivo. J Clin Endocrinol Metab 65:792-795 (1987).
47. Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Morrill A, Warram J. The effect of a low-fat diet on estrogen metabolism. J Clin Endocrinol 64:1246-1250 (1987).
48. Michnovicz JJ, Bradlow HL. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 16:59-66 (1991).
49. Hoffman AR, Majchrowicz E, Poth A, Paul SM. Ethanol reduces hepatic estrogen-2-hydroxylase activity in the male rat. Life Sciences 29:789-794 (1981).